Abdulraheem Yacoub, MD, on Advancing Outcomes for Patients With Myelofibrosis and Myeloproliferative Neoplasms

Video

CancerNetwork® spoke with Abdulraheem Yacoub, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how predictors of response to therapy may be just as important as the development of new therapies for advancing outcomes in myelofibrosis and myeloproliferative neoplasms.

CancerNetwork® sat down with Abdulraheem Yacoub, MD, to discuss some of the data to come out of the American Association for Cancer Research (AACR) Annual Meeting 2021. He explained that predictors of response to therapy and the incorporation of early transplantation in these patients had the potential to significantly influence the field.

Transcript:

The next step in the advancements of myelofibrosis and myeloproliferative neoplasms is to be able to predict responses in patients. There are many agents in development. There are many novel drugs with very unique and different mechanisms of actions. Although completing all these clinical trials is necessary to try to define the data and find if this drug will help patients, it’s very challenging to complete all those trials simultaneously. The next wave of improvement in patient outcomes is to try to be able to identify early predictors of response. And in this way, hopefully, the treatment for myelofibrosis will be more individualized and will be more personalized. [Clinicians] will be, based on the baseline biomarkers, more likely to predict [response to] different therapies and hopefully, that will improve outcomes substantially.

Also, trying to incorporate more transplantation early on in myelofibrosis, we try also to identify which therapies can improve patient outcomes through the transplant or against transplant or maybe make patients more likely to have a successful transplant. So that’s also an area for improvement that we’re hopefully going to hear more about in the future.

Recent Videos
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content